v3.26.1
SEGMENT INFORMATION (Tables)
6 Months Ended
Jun. 30, 2026
SEGMENT INFORMATION  
Schedule of segment revenue and significant segment expenses

Rare Neurological Diseases Segment

Three Months Ended June 30, 

Six Months Ended June 30, 

2026

2025

2026

2025

Net product revenue

$

261,280

$

200,489

$

476,667

$

385,222

Less:

Cost of product sold (a)

63,191

38,147

107,696

70,134

Research and development (b)

44,034

33,046

79,052

65,284

Sales and marketing (c)

32,311

28,421

62,210

56,388

General and administrative (d)

16,884

20,334

37,282

38,212

Depreciation and amortization

5,968

5,967

11,936

11,935

Stock-based compensation

9,576

11,394

19,884

23,844

Interest expense

3,070

3,646

6,304

7,482

Interest income

(7,072)

(5,296)

(12,829)

(10,340)

Income tax expense

17,834

9,861

25,033

21,478

Other segment items (e)

 

53

 

15,193

 

32,180

 

15,469

Consolidated net income

$

75,431

$

39,776

$

107,919

$

85,336

(a)Cost of product sold excluding depreciation.
(b)Research and development excluding stock-based compensation and IPR&D.
(c)Sales and marketing excluding stock-based compensation.
(d)General and administrative excluding stock-based compensation and amortization.
(e)Other segment items include other expense, net and IPR&D charges.